Literature DB >> 1995769

Hypoglycaemic episodes during intensified insulin treatment: increased frequency but no effect on cognitive function.

P Reichard1, A Berglund, A Britz, S Levander, U Rosenqvist.   

Abstract

Ninety-seven patients with insulin dependent diabetes mellitus (IDDM) were randomized to intensified conventional treatment (ICT, n = 44) or regular treatment (RT, n = 53). The mean HbA1c level (+/- SEM) was reduced from 9.5 +/- 0.2% to 7.4 +/- 0.1% in the ICT group (P less than 0.001), and from 9.4 +/- 0.2% to 9.0 +/- 0.2% (P less than 0.01) in the RT group. The difference between the groups was significant (P less than 0.001). During a period of 3 years, 57% of the ICT patients (95% confidence interval 44-73%) and 23% of the RT patients (95% CI, 11-34%) (P less than 0.001) had at least one episode of serious hypoglycaemia, with the need for third-party assistance or resulting in coma. Eighteen of the 32 ICT patients who initially had adrenergic symptoms during hypoglycaemia changed to predominantly neuroglycopenic symptoms. This was the case with only 8 of 38 RT patients (P less than 0.01). The change in symptoms was related to the increased frequency of serious hypoglycaemia, but neither symptoms nor frequency of hypoglycaemia bor any relationship to insulin dose, body mass index, duration of diabetes or autonomic nerve function. The results of several neuropsychological tests did not differ between the groups at baseline, and did not change during the study. There were no signs of deteriorating cognitive function in the patients with serious hypoglycaemic episodes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995769     DOI: 10.1111/j.1365-2796.1991.tb00299.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  11 in total

Review 1.  Clinical evidence: glycaemic control in diabetes.

Authors:  W H Herman
Journal:  BMJ       Date:  1999-07-10

Review 2.  Current status of clinical and experimental researches on cognitive impairment in diabetes.

Authors:  Xiao-chun Liang; Sai-shan Guo; Nobuyoshi Hagino
Journal:  Chin J Integr Med       Date:  2006-03       Impact factor: 1.978

3.  Brain metabolism after recurrent insulin induced hypoglycaemic episodes: a PET study.

Authors:  H Chabriat; C Sachon; M Levasseur; A Grimaldi; S Pappata; D Rougemont; M C Masure; A De Recondo; Y Samson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 4.  A risk-benefit assessment of conventional versus intensive insulin therapy.

Authors:  P Reichard
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

5.  Intensified conventional insulin treatment and neuropsychological impairment.

Authors:  P Reichard; A Britz; U Rosenqvist
Journal:  BMJ       Date:  1991-12-07

6.  Cognitive efficiency declines over time in adults with Type 1 diabetes: effects of micro- and macrovascular complications.

Authors:  C M Ryan; M O Geckle; T J Orchard
Journal:  Diabetologia       Date:  2003-06-18       Impact factor: 10.122

Review 7.  Cerebral function in diabetes mellitus.

Authors:  G J Biessels; A C Kappelle; B Bravenboer; D W Erkelens; W H Gispen
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

8.  Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.

Authors:  E Stenninger; J Aman
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

Review 9.  Hypoglycemia induced by insulin as a triggering factor of cognitive deficit in diabetic children.

Authors:  Vanessa Rodrigues Vilela; Any de Castro Ruiz Marques; Christiano Rodrigues Schamber; Roberto Barbosa Bazotte
Journal:  ScientificWorldJournal       Date:  2014-03-23

Review 10.  Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.

Authors:  Pernille Kähler; Berit Grevstad; Thomas Almdal; Christian Gluud; Jørn Wetterslev; Søren Søgaard Lund; Allan Vaag; Bianca Hemmingsen
Journal:  BMJ Open       Date:  2014-08-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.